Insignificant effect of secretin in rodent models of polycystic kidney and liver disease

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 7, 2012, Pages

  Wang, Xiaofang ^a   Ye, Hong ^a   Ward, Christopher J ^a   Chu, Jessica Y S ^b   Masyuk, Tatyana V ^a   Larusso, Nicholas F ^a   Harris, Peter C ^a   Chow, Billy K C ^b   Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Autosomal dominant polycystic kidney disease; Cyclic AMP; Polycystic kidney disease; Secretin; Secretin receptor; Vasopressin

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; MESSENGER RNA; RECEPTOR PROTEIN; SECRETIN; SECRETIN RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; KIDNEY POLYCYSTIC DISEASE; LIVER POLYCYSTIC DISEASE; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SECRETIN BLOOD LEVEL; TARGET ORGAN; URINE LEVEL;

EID: 84867115802     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00242.2012     Document Type: Article

References (43)

1. Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Consugar MB, Milliner DM, King BF, Torres VE, Harris PC. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 85: 1-21, 2006.
2. Alpini G, Glaser S, Robertson W, Rodgers RE, Phinizy JL, Lasater J, LeSage GD. Large but not small intrahepatic bile ducts are involved in secretin-regulated ductal bile secretion. Am J Physiol Gastrointest Liver Physiol 272: G1064-G1074, 1997.
3. Alpini G, Glaser SS, Ueno Y, Rodgers R, Phinizy JL, Francis H, Baiocchi L, Holcomb LA, Galigiuri A, Lesage F. Bile acid feeling induces cholangiocyte proliferatio and secretion: evidence for bile acidredulated ductal secretion. Gastroenterology 116: 179-186, 1999.
4. Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 81: 569-578, 1988.
5. Banales JM, Masyuk TV, Bogert PS, Huang BQ, Gradilone SA, Lee SO, Stroope AJ, Masyuk AI, Medina JF, LaRusso NF. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 173: 1637-1646, 2008.
6. Charlton CG, Quirion R, Handelmann GE, Miller RL, Jensen RT, Finkel MS, O'Donohue TL. Secretin receptors in the rat kidney: adenylate cyclase activation and renal effects. Peptides 7: 865-871, 1986.
7. Chey WY, Chang TM. Secretin 100 years later. J Gastroenterol 38: 1025-1035, 2003.
8. Chey WY, Lee YH, Hendricks JG, Rhodes RA, Tai HH. Plasma secretin concentrations in fasting and postprandial state in man. Am J Dig Dis 23: 981-988, 1978.
9. Chu JY, Cheng CY, Lee VH, Chan YS, Chow BK. Secretin and body fluid homeostasis. Kidney Int 79: 280-287, 2011.
10. Chu JY, Chung SC, Lam AK, Tam S, Chung SK, Chow BK. Phenotypes developed in secretin receptor-null mice indicated a role for secretin in regulating renal water reabsorption. Mol Cell Biol 27: 2499-2511, 2007.
11. Chu JY, Yung WH, Chow BK. Secretin: a pleiotrophic hormone. Ann NY Acad Sci 1070: 27-50, 2006.
12. Everson G, Emmett M, Brown W, Redmond P, Thickman D. Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin. Hepatology 11: 557-565, 1990.
13. Gattone VH, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003.
14. Glaser S, Lam IP, Franchitto A, Gaudio E, Onori P, Chow BK, Wise C, Kopriva S, Venter J, White M, Ueno Y, Dostal D, Carpino G, Mancinelli R, Butler W, Chiasson V, DeMorrow S, Francis H, Alpini G. Knockout of secretin receptor reduces large cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct ligation. Hepatology 52: 204-214, 2010.
15. Grantham JJ. Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach. Kidney Int 64: 1157-1162, 2003.
16. Green GM, Taguchi S, Friestman J, Chey WY, Liddle RA. Plasma secretin, CCK, and pancreatic secretion in response to dietary fat in the rat. Am J Physiol Gastrointest Liver Physiol 256: G1016-G1021, 1989.
17. Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 111: 1072-1080, 2003.
18. Gunnes P, Reikeras O. Distribution of the increased cardiac output secondary to the vasodilating and inotropic effects of secretin. Scand J Clin Lab Invest 47: 383-388, 1987.
19. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 6: 2499-2507, 2011.
20. Hirata K, Nathanson MH. Bile duct epithelia regulate biliary bicarbonate excretion in normal rat liver. Gastroenterology 121: 396-406, 2001.
21. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR III, Rossetti S, Harris PC, LaRusso NF, Torres VE. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21: 1052-1061, 2010.
22. Kato A, Gores GJ, LaRusso NF. Secretin stimulates exocytosis in isolated bile duct epithelial cells by a cyclic AMP-mediated mechanism. J Biol Chem 267: 15523-15529, 1992.
23. Kim MS, Lee KY, Chey WY. Plasma secretin concentrations in fasting and postprandial states in dog. Am J Physiol Endocrinol Metab 236: E539-E544, 1979.
24. Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 59: 126-136, 2001.
25. Lam IP, Siu FK, Chu JY, Chow BK. Multiple actions of secretin in the human body. Int Rev Cytol 265: 159-190, 2008.
26. Lenzen R, Alpini G, Tavoloni N. Secretin stimulates bile ductular secretory activity through the cAMP system. Am J Physiol Gastrointest Liver Physiol 263: G527-G532, 1992.
27. Lesage G, Glaser SS, Gubba S, Robertson WE, Phinizy JL, Lasater J, Rodgers RE, Alpini G. Regrowth of the rat biliary tree after 70% partial hepatectomy is coupled to increased secretin-induced ductal secretion. Gastroenterology 111: 1633-1644, 1996.
28. Lu Y, Owyang C. Secretin at physiological doses inhibits gastric motility via a vagal afferent pathway. Am J Physiol Gastrointest Liver Physiol 268: G1012-G1016, 1995.
29. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 132: 1104-1116, 2007.
30. Mennone A, Alvaro D, Cho W, Boyer JL. Isolation of small polarized bile duct units. Proc Natl Acad Sci USA 92: 6527-6531, 1995.
31. Paliard P, Partensky C. [Polycystic liver disease with abdominal pain and jaundice treated by two successive "fenestration" procedure (author's transl)]. Gastroenterol Clin Biol 4: 854-857, 1980.
32. Romano G, Giagu P, Favret G, Bartoli E. Dual effect of secretin on nephron filtration and proximal reabsorption depending on the route of administration. Peptides 21: 723-728, 2000.
33. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Enelordache B, Remuzzi G, Epstein FH. Safety and efficacy of long-acting somatostatin treatment in autosomal dominant polcysytic kidney disease. Kidney Int 68: 206-216, 2005.
34. Tietz PS, Marinelli RA, Chen XM, Huang B, Cohn J, Kole J, McNiven MA, Alper S, LaRusso NF. Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes. J Biol Chem 278: 20413-20419, 2003.
35. Torres VE. Cyclic AMP, at the hub of the cystic cycle. Kidney Int 66: 1283-1285, 2004.
36. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007.
37. Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 57: 692-699, 2011.
38. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004.
39. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137: 1661-1668 e1661-1662, 2009.
40. Wallace DP. Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta 1812: 1291-1300, 2011.
41. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008.
42. Wu G, D'Agati V, Cai Y, Markowitz G, Park J, Reynolds D, Maeda Y, Le T, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S. Somatic inactivation of PKD2 results in polycystic kidney disease. Cell 93: 177-188, 1998.
43. Yamaguchi T, Pelling J, Ramaswamy N, Eppler J, Wallace D, Nagao S, Rome L, Sullivan L, Grantham J. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000.